Health

Results: 1537-1548 of 10153

Europe's Healthcare IT Market Enters the 2027 Readiness Cycle as Black Book Names 26 Top Client-Rated Vendors During HIMSS26 Week in Copenhagen

AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

THE MENOPAUSE-WHAT YOUR FAMILY SHOULD KNOW

Ophthalmologist Roberto Pinelli explains, in an engaging personal narrative style, his unique methods for using a combination of light, sound, and nutraceuticals to non-invasively activate the pineal gland to promote cellular rejuvenation, decrease aging, and improve overall well-being. Supported by case studies and peer-reviewed research, Pinelli’s method centers on using photons to convey vibrational energy through the eyes to target areas of the body with the sinergic use of sound vibrations and specific nutraceuticals. He shows the potent effects this has on overall wellbeing and mental health as it can improve memory, mental clarity, and self-awareness. His techniques also have positive effects on the body such as helping to heal degenerative diseases like AMD, retinal degenerations, Alzheimer’s, rheumatoid arthritis, and Parkinson’s.

SERI Lugano Launches International Scientific Outreach Initiative on Light-Based Neuroscience and Pineal Gland Research

PR Newswire associated0

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

FDA Grants Breakthrough Therapy Designation to VERTANICAL's VER-01, a First-in-Class Non-Opioid Investigational Treatment for Chronic Low Back Pain

HistoSonics Edison® Histotripsy System

HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion

Business Wire associated0

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

THREE IN FOUR ALCOHOL DEATHS ARE CAUSED BY LIVER DISEASE. SCOTTISH DEATH RATE REMAINS ONE AND A HALF TIMES ENGLAND'S

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy

VahatiCor CEO, Harry D. Rowland, Ph.D.

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer